LBA75 Prospective randomised phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer: Results of the SUNNIFORECAST trial
Lars Bergmann, Marit Ahrens, L. Albiges, M. Gross Goupil, Ekaterini Boleti, Gwénaëlle Gravis, A. Flechon, M-O.J. Grimm, S. Rausch, P. Barthelemy, D.E. Castellano Gauna, B. Mellado González, P. Ivanyi, A. Floercken, C. Suarez Rodriguez, J.P. Maroto Rey, V. Gruenwald, Iris Burkholder, A. Hartmann, John B.A.G. Haanen
Topics & Concepts
MedicineNivolumabIpilimumabInternal medicineOncologyRenal cell carcinomaStandard of careCancerImmunotherapyRenal cell carcinoma treatmentEconomic and Financial Impacts of CancerCancer Immunotherapy and Biomarkers